David Voduc

David Voduc

UNVERIFIED PROFILE

Are you David Voduc?   Register this Author

Register author
David Voduc

David Voduc

Publications by authors named "David Voduc"

Are you David Voduc?   Register this Author

22Publications

1001Reads

50Profile Views

Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up.

Breast Cancer Res Treat 2018 Feb 20;168(1):107-115. Epub 2017 Nov 20.

Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, 509-2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-017-4583-z
Publisher Site
http://dx.doi.org/10.1007/s10549-017-4583-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823734PMC
February 2018

Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.

J Clin Oncol 2015 Jun 11;33(18):2035-40. Epub 2015 May 11.

Fei-Fei Liu, Anthony W. Fyles, Wei Shi, Susan J. Done, Naomi Miller, Melania Pintilie, and David R. McCready, Princess Margaret Cancer Centre/University Health Network; Sharon Nofech-Mozes, Sunnybrook Odette Cancer Center; Martin C. Chang, Mt. Sinai Hospital, University of Toronto, Toronto; Timothy J. Whelan, Juravinski Cancer Centre, McMaster University, Hamilton, ON; David Voduc, Torsten O. Nielsen, and Lorna M. Weir, British Columbia Cancer Agency, Vancouver; and Ivo A. Olivotto, British Columbia Cancer Agency, Victoria, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.7999DOI Listing
June 2015

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Oncologist 2015 May 23;20(5):474-82. Epub 2015 Apr 23.

Lineberger Comprehensive Cancer Center and Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; Servicio de Oncología Médica, Instituto de Investigacion Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada; Translation Genomics Unit, Vall d´Hebron Institute of Oncology, Barcelona, Spain; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain; Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain; GEICAM, Madrid, Spain; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; Department of Medicine, Washington University, St. Louis, Missouri, USA; Department of Oncology, Hospital of Prato, Istituto Toscani Tumori, Florence, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425383PMC
May 2015

Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?

Breast Cancer Res Treat 2014 Oct 11;147(3):617-29. Epub 2014 Sep 11.

BC Cancer Agency, Vancouver Cancer Centre, University of British Columbia, 600 W 10th Avenue, Vancouver, BC, V5Z 4E6, Canada,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3125-1DOI Listing
October 2014

Metastatic behavior of breast cancer subtypes.

J Clin Oncol 2010 Jul 24;28(20):3271-7. Epub 2010 May 24.

Vancouver Clinic, Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.25.9820DOI Listing
July 2010

HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients.

Ann Surg 2010 Jun;251(6):1107-16

Department of Surgery, St. Paul's Hospital, University of British Columbia, Vancouver, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0b013e3181dbb77eDOI Listing
June 2010

Breast cancer subtypes and the risk of local and regional relapse.

J Clin Oncol 2010 Apr 1;28(10):1684-91. Epub 2010 Mar 1.

Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.24.9284DOI Listing
April 2010

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

J Natl Cancer Inst 2009 May 12;101(10):736-50. Epub 2009 May 12.

Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/djp082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684553PMC
May 2009

Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.

Clin Breast Cancer 2008 Dec;8 Suppl 4:S171-8

Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2008.s.014DOI Listing
December 2008

The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.

Hum Pathol 2008 Oct 11;39(10):1431-7. Epub 2008 Jul 11.

Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2008.03.004DOI Listing
October 2008

Tissue microarrays in clinical oncology.

Semin Radiat Oncol 2008 Apr;18(2):89-97

Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semradonc.2007.10.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292098PMC
April 2008

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Clin Cancer Res 2008 Mar;14(5):1368-76

Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1658DOI Listing
March 2008

GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.

Cancer Epidemiol Biomarkers Prev 2008 Feb;17(2):365-73

Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia, Canada V5Z 4E6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-06-1090DOI Listing
February 2008

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases.

Breast Cancer Res Treat 2008 Jan 13;107(2):249-57. Epub 2007 Mar 13.

Department of Pathology, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-007-9546-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2137942PMC
January 2008

Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002.

Urology 2006 Mar;67(3):594-8

Radiation Therapy Program, British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2005.09.050DOI Listing
March 2006